Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Boehringer Ingelheim · Phase 1 · Completed · Enrollment 88

NCT05751226

EudraCT 2022-002733-34

ArmPopulationDoseWeeksEstimandWeight change
BI 1820237 treatment groupObesity or overweightn/rn/rn/rn/r
Placebo groupObesity or overweightn/rn/rn/rn/r
BI 1820237 + semaglutide treatment groupObesity or overweightn/rn/rn/rn/r
placebo + semaglutide groupObesity or overweightn/rn/rn/rn/r
BI 1820237 + BI 456906 treatment groupObesity or overweightn/rn/rn/rn/r
placebo + BI 456906 groupObesity or overweightn/rn/rn/rn/r